Intravascular low intensity laser therapy (ILILT) was originally put forward in USA in 1982, but popularized in Russia in
1980s and in China in 1990s, respectively. A randomized placebo-controlled study has shown ILILT clinical efficacy in
patients suffering from rheumatoid arthritis. As Chinese therapeutic applications of ILILT were the most widely in the world,
its basic research, such as intracellular signal transduction research, blood research in vitro, animal blood research in vivo,
human blood research in vivo and traditional Chinese medicine research, was also very progressive in China. Its basic studies
will be reviewed in terms of the biological information model of photobiomodulation in this paper. ILILT might work in view
of its basic studies, but the further randomized placebo-controlled trial and the further safety research should be done.